The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10491 malaria professionals are enjoying the free benefits of MalariaWorld today


Prevalence of mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against African Plasmodium falciparum isolates

June 8, 2020 - 15:27 -- Open Access
Francis Tsombeng Foguim, Hervé Bogreau, Mathieu Gendrot, Joel Mosnier, Isabelle Fonta, Nicolas Benoit, Rémy Amalvict, Marylin Madamet, Sharon Wein and Bruno Pradines
Malaria Journal 2020 19:201, 5 June 2020

The Plasmodium falciparum chloroquine transporter gene (pfcrt) is known to be involved in chloroquine and amodiaquine resistance, and more particularly the mutations on the loci 72 to 76 localized within the second exon. Additionally, new mutations (T93S, H97Y, C101F, F145I, M343L, C350R and G353V) were recently shown to be associated with in vitro reduced susceptibility to piperaquine in Asian or South American P. falciparum strains. However, very few data are available on the prevalence of these mutations and their effect on parasite susceptibility to anti-malarial drugs, and more particularly piperaquine in Africa.

Not Open Access | Plasmodium faciparum carrying pfk13 polymorphisms harbour the SVMNT allele of pfcrt in north-western Indonesia

May 13, 2020 - 14:38 -- NOT Open Access
Lubis IND, Wijaya H, Lubis M, Lubis CP, Beshir KB, Sutherland CJ
Antimicrob Agents Chemother. 2020 May 11. pii: AAC.02539-19

Artemisinin-based combination therapy is the first-line antimalarial regimen in Indonesia. Susceptibility of Plasmodium falciparum to artemisinin is falling in the Greater Mekong sub-Region, but it is not known whether the efficacy of current combinations is also threatened in nearby Sumatera. We evaluated the genetic loci pfcrt, pfmdr1 and pfk13, considered to be under selection by artemisinin combination therapy, among 404 P. falciparum infections identified by PCR detection in a cross-sectional survey of 3,731 residents of three Regencies.

NOT Open Access | Turning the tide: targeting PfCRT to combat drug-resistant P. falciparum

May 7, 2020 - 13:28 -- NOT Open Access
Small-Saunders JL, Hagenah LM, Fidock DA
Nat Rev Microbiol. 2020 May;18(5):261-262

Resistance to the current first-line antimalarials threatens the control of malaria caused by the protozoan parasite Plasmodium falciparum and underscores the urgent need for new drugs with novel modes of action.

Molecular surveillance of Pfcrt and k13 propeller polymorphisms of imported Plasmodium falciparum cases to Zhejiang Province, China between 2016 and 2018

February 10, 2020 - 16:08 -- Open Access
Xiaoxiao Wang, Wei Ruan, Shuisen Zhou, Fang Huang, Qiaoyi Lu, Xinyu Feng and He Yan
Malaria Journal 2020 19:59, 4 February 2020

Resistance to anti-malarial drugs hinders malaria elimination. Monitoring the molecular markers of drug resistance helps improve malaria treatment policies. This study aimed to assess the distribution of molecular markers of imported Plasmodium falciparum infections.

Analysis of Plasmodium falciparum Pfcrt and Pfmdr1 genes in parasite isolates from asymptomatic individuals in Southeast Nigeria 11 years after withdrawal of chloroquine

October 8, 2019 - 15:12 -- Open Access
Moses N. Ikegbunam, Charles N. Nkonganyi, Bolaji N. Thomas, Charles O. Esimone, Thirumalaisamy P. Velavan and Olusola Ojurongbe
Malaria Journal 2019 18:343, 7 October 2019

A reversal of chloroquine (CQ) resistance following a period of withdrawal has raised the possibility of its re-introduction. This study evaluated the current prevalence of Pfcrt and Pfmdr1 alleles in Plasmodium falciparum isolates, 11 years after CQ withdrawal in Southeast Nigeria.

Medical Condition: 
Subscribe to RSS - Pfcrt